TLQP 21

Pricing Availability   Qty
Description: VGF-derived peptide
Purity: ≥95% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (3)

Biological Activity for TLQP 21

TLQP 21 is a VGF-derived peptide; spans residues 556-576 of the precursor sequence. Protects cerebellar granule cells (CGCs) from serum and potassium deprivation-induced apoptosis. Increases energy expenditure and prevents early phase diet-induced diabetes.

Technical Data for TLQP 21

M. Wt 2432.77
Formula C107H170N40O26
Sequence TLQPPASSRRRHFHHALPPAR
Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 869988-94-3
PubChem ID 16158480
InChI Key PWWMOXVVMRPYJS-IWCKOKPFSA-N
Smiles [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for TLQP 21

Solubility Soluble to 1 mg/ml in water

Product Datasheets for TLQP 21

Certificate of Analysis / Product Datasheet
Select another batch:

References for TLQP 21

References are publications that support the biological activity of the product.

Severini et al (2008) TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cell death induced by serum and potassium deprivation. J.Neurochem. 104 534 PMID: 18173805

Bartolomucci et al (2006) TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc.Natl.Acad.Sci. USA 103 14584

Jethwa et al (2007) VGF-derived peptide, TLQP-21, regulates food intake and body weight in Siberian hamsters. Endocrinol. 148 4044


If you know of a relevant reference for TLQP 21, please let us know.

Keywords: TLQP 21, TLQP 21 supplier, VGF-derived, peptide, Neurotrophin, Receptors, TLQP21, Other, Apoptosis, Trk, 3051, Tocris Bioscience

1 Citation for TLQP 21

Citations are publications that use Tocris products. Selected citations for TLQP 21 include:

Hannedouche et al (2013) Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. Front Pharmacol 288 27434 PMID: 23940034


Do you know of a great paper that uses TLQP 21 from Tocris? Please let us know.

Reviews for TLQP 21

There are currently no reviews for this product. Be the first to review TLQP 21 and earn rewards!

Have you used TLQP 21?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.